Barclays raised the firm’s price target on Celldex (CLDX) to $48 from $45 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex reports Q1 EPS ($1.18), consensus ($1.13)
- Celldex sees funds sufficient to fund current planned operations through 2028
- CLDX Earnings this Week: How Will it Perform?
- Morning News Wrap-Up, 4/20/26: Today’s Biggest Stock Market Stories!
- A Top Wall Street Analyst ‘Can’t Ignore’ Celldex Stock (CLDX)